Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
Pfizer drops another early cancer candidate from Seagen
The decision to scrap the ADC was made for “business reasons” and “was not related to any safety concerns or requests from regulatory authorities.”
Darren Incorvaia
Mar 19, 2026 12:56pm
Bicycle pumps brakes on lead program, deflates headcount by 30%
Mar 17, 2026 11:14am
CNS Pharma wipes glioblastoma pipeline clean in strategic pivot
Mar 11, 2026 10:30am
Ono’s Deciphera drops early-stage solid tumor drug
Mar 3, 2026 7:47pm
Werewolf weighs sale or merger as cash reserves whimper
Feb 24, 2026 5:23pm
Gilead pens $1.5B Genhouse deal for synthetic lethal therapy
Feb 16, 2026 2:00pm
